Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pyrotinib with Trastuzumab and Abraxane in HER2-enriched Breast Cancer
NCT05659056Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2022
- Primary completion
- Apr 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Pathological Complete Response at 5 months. Started Nov 2022; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05659056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05659056.